Bevacizumab

Statut de médicament

Description générale

Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.

INN	Bevacizumab
Codes ATC	S01LA08 L01FG01
Type de médicament	Biological agent
Historique des statuts LME	Ajouté pour la première fois en 2013 (TRS 985) pour Age-related macular degeneration Demande refusée en 2025 (TRS 1064) pour Hepatocellular carcinoma of liver
Wikipédia	Bevacizumab
DrugBank	Bevacizumab

Recommandations

Section Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Indications

Age-related macular degeneration

Section Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Indications

Hepatocellular carcinoma of liver